Dyne Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Dyne Therapeutics is John Cox, benoemd in Mar2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.036% van de aandelen van het bedrijf, ter waarde $ 1.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 5 jaar.

Belangrijke informatie

John Cox

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	3.4yrs
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12

Dyne Therapeutics EPS beats by $0.10

May 06

CEO

John Cox (61 yo)

less than a year

Tenure

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Cox	CEO, President & Director	less than a year	geen gegevens	0.036% $ 1.1m
Romesh Subramanian	Co-Founder & Advisor	no data	US$4.37m	geen gegevens
Richard Scalzo	Senior VP and Head of Finance & Administration	4.3yrs	geen gegevens	0.0058% $ 174.3k
John Najim	Chief Technical Officer	1.6yrs	geen gegevens	geen gegevens
Oxana Beskrovnaya	Chief Scientific Officer	3.4yrs	US$1.49m	0.033% $ 990.5k
Amy Reilly	Senior VP and Head of Corporate Communications & Investor Relations	4.3yrs	geen gegevens	geen gegevens
Daniel Wilson	Senior VP & Head of Legal	4.4yrs	geen gegevens	geen gegevens
Lucia Celona	Chief Human Resource Officer	less than a year	geen gegevens	geen gegevens
Debra Feldman	Chief Regulatory Affairs Officer	4.5yrs	geen gegevens	geen gegevens
Ashish Dugar	Chief Medical Affairs Officer	3.8yrs	geen gegevens	geen gegevens
Johanna Friedl-Naderer	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens
Douglas Kerr	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

3.4yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DYN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Cox	CEO, President & Director	less than a year	geen gegevens	0.036% $ 1.1m
Sudhir Agrawal	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Edward Hurwitz	Independent Director	6yrs	US$250.17k	0% $ 0
David Lubner	Independent Director	4.7yrs	US$264.17k	0.053% $ 1.6m
Jason Rhodes	Independent Chairman	6.9yrs	US$283.17k	0% $ 0
Dirk Kersten	Independent Director	6yrs	US$262.67k	0% $ 0
Francesco Muntoni	Member of Scientific Advisory Board	4.3yrs	geen gegevens	geen gegevens
Louis Kunkel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nancy Andrews	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Catherine Stehman-Breen	Independent Director	5.4yrs	US$253.92k	0.088% $ 2.7m
Charles Thornton	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Statland	Member of Scientific Advisory Board	4.5yrs	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DYN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Dyne Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics, Inc Announces Management Changes

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Recent updates

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

CEO, President & Director recently bought US$1.1m worth of stock

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Dyne Therapeutics, Inc Announces Management Changes

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Price target increased by 8.9% to US$50.00

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

Chief Operating Officer notifies of intention to sell stock

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $325.5 million.

New major risk - Shareholder dilution

Chief Scientific Officer notifies of intention to sell stock

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne Therapeutics, Inc., Annual General Meeting, May 22, 2024

Dyne Therapeutics, Inc. Announces Chief Executive Officer Changes

CEO, President & Director recently sold US$223k worth of stock

Chief Operating Officer recently sold US$725k worth of stock

Price target increased by 8.3% to US$37.56

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

CEO, President & Director notifies of intention to sell stock

Chief Business Officer exercised options and sold US$476k worth of stock

New major risk - Shareholder dilution

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.125 million.

Dyne Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

Chief Business Officer notifies of intention to sell stock

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Chief Operating Officer notifies of intention to sell stock

New major risk - Financial position

CEO, President & Director notifies of intention to sell stock

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

New major risk - Financial position

Insufficient new directors

CEO, President & Director recently sold US$618k worth of stock

CEO, President & Director notifies of intention to sell stock

Dyne Therapeutics, Inc. Announces Resignation of Dr. Lawrence Klein as Board Member

Insufficient new directors

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Price target increased by 9.6% to US$28.50

Insider exercised options and sold US$133k worth of stock

Insider notifies of intention to sell stock

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dyne Therapeutics, Inc. Receives Fda Fast Track Designation for Dyne-251 for the Treatment of Duchenne Muscular Dystrophy

CEO, President & Director exercised options and sold US$2.4m worth of stock

Dyne Therapeutics, Inc. Presents Preclinical Data from Its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 At World Muscle Society 2022 Congress

Dyne Therapeutics, Inc. Prioritizes its Focus and Resources on its Clinical Programs, DYNE-101 in DM1 and DYNE-251 in DMD

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne Therapeutics, Inc. Appoints Francesco Bibbiani as Senior Vice President, Head of Development

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne Therapeutics, Inc. Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

High number of new directors

Price target decreased to US$24.67

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Dyne Therapeutics, Inc. Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Dyne Therapeutics, Inc. Presents New In Vivo Data from DYNE-101

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

High number of new directors

Dyne Therapeutics, Inc., Annual General Meeting, Jun 03, 2022

Price target decreased to US$30.25

Dyne Therapeutics, Inc. Appoints Carlo Inert, M.D., to Its Board of Directors

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely